Nov 12, 2019 / 01:00PM GMT
Operator
Good morning, and welcome to Editas Medicine's Third Quarter 2019 Conference Call.
(Operator Instructions) Please be advised that this call is being recorded at the company's request.
I would now like to turn the call over to Mark Mullikin, Vice President of Finance and Investor Relations at Editas Medicine.
Mark J. Mullikin - Editas Medicine, Inc. - Senior Director of Finance & IR
Thank you, operator. Good morning, everyone, and welcome to our third quarter 2019 conference call. Earlier this morning, we issued 2 press releases that will be discussed on this call. The first announces an amendment to our long-standing collaboration with Celgene. The second press release provides our financial results and corporate updates for the third quarter of 2019.
A replay of today's call will be available on the Investors and Media section of our website approximately 2 hours after its completion. After our prepared remarks, we will open the call for Q&A.
As a reminder, various remarks that we make during this call about the
Q3 2019 Editas Medicine Inc Earnings Call Transcript
Nov 12, 2019
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers